Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Genome Diagnostics Laboratory, |
RCV001847552 | SCV002105112 | pathogenic | Hereditary spastic paraplegia | 2016-12-12 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001885404 | SCV002151245 | pathogenic | Spastic paraplegia | 2023-12-13 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Asn3040Lysfs*5) in the SACS gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 1540 amino acid(s) of the SACS protein. This variant is present in population databases (no rsID available, gnomAD 0.01%). This premature translational stop signal has been observed in individual(s) with hereditary spastic paraplegia (PMID: 29449188). This variant is also known as c.9119dupA; p.Asn3040Lysfs*4. ClinVar contains an entry for this variant (Variation ID: 1344007). This variant disrupts a region of the SACS protein in which other variant(s) (p.Asn4549Asp) have been determined to be pathogenic (PMID: 15156359, 21507954). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. |
Fulgent Genetics, |
RCV005006088 | SCV005634271 | likely pathogenic | Charlevoix-Saguenay spastic ataxia | 2024-03-29 | criteria provided, single submitter | clinical testing |